APR 06, 2016 9:00 AM PDT

Liquid biopsy and NGS: moving from sample to insight

Speaker

Abstract

Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment.  Liquid biopsies provide us an easy and less intrusive way to monitor disease status.  The key challenge is the sensitivity and specificity of assays used to detect genetic variances in such small samples.  Recent advances in NGS have made it the ideal approach for the comprehensive analysis of the mutational landscape of samples. Specifically, the ability to enrich certain genomic targets known, or suspected, to harbor driver mutations prior to NGS is allowing researchers to achieve very deep levels of sequencing coverage, levels that cannot be achieved by either WGA or WES, thereby increasing the sensitivity of NGS assays. The ability to enrich genomic targets has also facilitated the use of liquid biopsies for the discovery of mutations that contribute to drug resistance. Several challenges remain though, mainly the specificity and uniformity of target enrichment approaches, the amount of required DNA, and the turnaround time needed to go from sample to insight. Attend this seminar to learn what solutions QIAGEN scientists have developed to overcome these challenges and how these solutions can be used to analyze mutations in a wide range of samples such as FFPE, cfDNA, and CTCs, thereby enabling researchers to use solid and liquid biopsies to continuously monitor the disease status. 
 


Show Resources
You May Also Like
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
JAN 21, 2021 8:00 AM PST
JAN 21, 2021 8:00 AM PST
Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
APR 06, 2016 9:00 AM PDT

Liquid biopsy and NGS: moving from sample to insight


Specialty

Clinical Diagnostics

Biotechnology

Biomarkers

Cancer Research

Oncology

Cancer

Molecular Diagnostics

Immuno-Oncology

Tumor

Molecular Biology

Dna

Drug Discovery

Cancer Diagnostics

Dna Sequencing

Next-Generation Sequencing

Geography

Europe50%

North America25%

Africa25%

Registration Source

Website Visitors100%

Job Title

Student25%

Medical Doctor/Specialist25%

Consultant25%

Lab Management25%

Organization

Independent Laboratories25%

Hospital25%

Industrial Company25%

Academic Institution25%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more